Study shows Seladelpar improves liver bio markers for PBC patients
In an oral presentation at the AASLD Liver Meeting November 2021, titled “Long-Term Safety and Efficacy of Seladelpar in Patients with Primary Biliary Cholangitis”1 Marlyn J. Mayo, MD, Professor and
Combination Therapy works for PBC
Study concludes that triple therapy with UDCA, OCA and fibrates is able to normalise biochemical liver tests and improve pruritus in patients with difficult‐to‐treat PBC. Read full study.
OCA real world experience
Since OCA (Ocaliva) was approved in the US in 2016 and Canada in 2017, there have been several studies to assess its effectiveness in PBC patients around the world. Here
CaNAL Patient Registry Update
The Canadian Network for Autoimmune Liver disease (CaNAL) is a longitudinal observational cohort study of patients diagnosed with Primary Biliary Cholangitis (PBC), Autoimmune Hepatitis (AIH), or overlap syndrome. This nationwide
Cholestasis-Associated Pruritus and Its Pruritogens
Jacqueline A. G. M. Langedijk, Ulrich H. Beuers and Ronald P. J. Oude Elferink* published March 9, 2021, frontiers in Medicine. “Cholestasis is the term for diminished or impaired bile
Prognostic Factors for Clinical Outcomes in Patients with PBC
This thesis, written by Dr. Carla Fiorella Murillo Perez was published January 2021. The study uses a large and globally representative cohort of patients with long-term follow-up to study various
CymaBay – Seladelpar RESPONSE Phase 3 study now enrolling
For more information see clinicaltrials.gov The following summary is provided by CymaBay Therapeutics. RESPONSE (study number CB8025-32048) is a Phase 3 clinical research study being conducted to learn more about
Elafibranor ELATIVE study now enrolling
The Phase 3 study will consist of Elafibranor 80mg for double blind period (52 to 104 weeks). After completion of the double blind period, participants will be offered the opportunity
EL-FIT program helps keep liver patients fit!
El-Fit offers a custom exercise program, tailored to meet the individual needs of liver patients. Using a friendly APP, the program allows patients to set goals and track progress, as